National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Citation data:

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, ISSN: 1523-6536, Vol: 21, Issue: 3, Page: 389-401.e1

Publication Year:
Usage 241
Abstract Views 227
Link-outs 14
Captures 27
Readers 25
Exports-Saves 2
Mentions 1
Blog Mentions 1
Social Media 4
Tweets 4
Citations 321
Citation Indexes 318
Clinical Citations 3
Repository URL:
Jagasia, Madan H; Greinix, Hildegard T; Arora, Mukta; Williams, Kirsten M; Wolff, Daniel; Cowen, Edward W; Palmer, Jeanne; Weisdorf, Daniel; Treister, Nathaniel S; Cheng, Guang-Shing; Kerr, Holly; Stratton, Pamela; Duarte, Rafael F; McDonald, George B; Inamoto, Yoshihiro; Vigorito, Afonso; Arai, Sally; Datiles, Manuel B; Jacobsohn, David; Heller, Theo; Kitko, Carrie L; Mitchell, Sandra A; Martin, Paul J; Shulman, Howard; Wu, Roy S; Cutler, Corey S; Vogelsang, Georgia B; Lee, Stephanie J; Pavletic, Steven Z; Flowers, Mary E D Show More Hide
Elsevier BV
Medicine; Clinical Trials as Topic--methods; Clinical Trials as Topic--standards; Graft vs Host Disease--diagnosis; Clinical Trials as Topic--methods; Clinical Trials as Topic--standards; Graft vs Host Disease--diagnosis; Pediatrics
Most Recent Tweet View All Tweets
Most Recent Blog Mention
article description
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.